Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PolyPid ( (PYPD) ) just unveiled an announcement.
On November 26, 2025, PolyPid Ltd. announced an increase in the maximum aggregate offering price of its ordinary shares from $8,250,000 to $15,000,000 under its Sales Agreement with Oppenheimer & Co. Inc. This strategic financial move is aimed at bolstering the company’s capital base, potentially enhancing its market position and providing additional resources to advance its business objectives.
The most recent analyst rating on (PYPD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of products designed to improve surgical outcomes. The company is headquartered in Petach Tikva, Israel, and is involved in the issuance and sale of ordinary shares to support its operations.
Average Trading Volume: 69,496
Technical Sentiment Signal: Hold
Current Market Cap: $58.5M
For a thorough assessment of PYPD stock, go to TipRanks’ Stock Analysis page.